These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15112269

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I, Sapia S, Pavlovsky S.
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [Abstract] [Full Text] [Related]

  • 43. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D.
    J Clin Oncol; 2005 Jun 20; 23(18):4179-91. PubMed ID: 15961765
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
    Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H, Shimoda T.
    Jpn J Clin Oncol; 2009 Sep 20; 39(9):595-600. PubMed ID: 19535387
    [Abstract] [Full Text] [Related]

  • 49. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E.
    Leuk Res; 2005 Jun 20; 29(6):649-52. PubMed ID: 15863204
    [Abstract] [Full Text] [Related]

  • 50. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R.
    Am J Hematol; 2005 Aug 20; 79(4):257-61. PubMed ID: 16044453
    [Abstract] [Full Text] [Related]

  • 51. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B.
    J Clin Oncol; 2006 Aug 01; 24(22):3604-10. PubMed ID: 16877727
    [Abstract] [Full Text] [Related]

  • 52. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.
    Cancer; 2006 Mar 01; 106(5):1099-109. PubMed ID: 16435387
    [Abstract] [Full Text] [Related]

  • 53. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O, Hofmann WK, Baldus CD, Thiel G, Serbent V, Schümann E, Thiel E, Blau IW.
    Exp Hematol; 2007 Feb 01; 35(2):221-9. PubMed ID: 17258071
    [Abstract] [Full Text] [Related]

  • 54. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 55. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
    de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES.
    Clin Cancer Res; 2008 Feb 01; 14(3):924-30. PubMed ID: 18245556
    [Abstract] [Full Text] [Related]

  • 56. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
    Cancer; 2007 Jul 15; 110(2):345-52. PubMed ID: 17559141
    [Abstract] [Full Text] [Related]

  • 57. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
    Jaroszewicz J, Januszkiewicz M, Flisiak R, Rogalska M, Kalinowska A, Wierzbicka I.
    Cytokine; 2008 Oct 15; 44(1):14-7. PubMed ID: 18656381
    [Abstract] [Full Text] [Related]

  • 58. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T, Yasuyama M, Kawauchi K.
    Am J Hematol; 2005 Jun 15; 79(2):136-41. PubMed ID: 15929101
    [Abstract] [Full Text] [Related]

  • 59. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
    Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R.
    J Hematother Stem Cell Res; 2002 Feb 15; 11(1):119-25. PubMed ID: 11847008
    [Abstract] [Full Text] [Related]

  • 60. Telomerase activity in myelodysplastic syndromes.
    Gürkan E, Tanriverdi K, Başlamişli F.
    Leuk Res; 2005 Oct 15; 29(10):1131-9. PubMed ID: 16111531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.